tbuckley/cabot-search huggingface dataset:
Randomized trial of inpatient palliative care in patients hospitalized for hematopoietic stem cell transplantation (HCT).
Authors: Areej El-Jawahri, Thomas William LeBlanc, Harry VanDusen, Lara Traeger, Joseph A. Greer, William F. Pirl, Vicki A. Jackson, Jason Telles, Alison Rhodes, Yi-Bin Albert Chen, Jennifer S. Temel
Journal: Journal of Clinical Oncology (2016)

103 Background: During HCT, patients experience physical and psychological symptoms that negatively impact their quality of life (QOL). We assessed the impact of an inpatient palliative care intervention on patient QOL, symptom burden, and mood during HCT hospitalization and at 3 months post-HCT. Methods: We randomized 160 patients with hematologic malignancies admitted for autologous or allogeneic HCT to an inpatient palliative care intervention (n=81) integrated with transplant care compared to transplant care alone (n=79). We used the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) to assess QOL, the Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire (PHQ-9) to assess mood, and Edmonton Symptom Assessment Scale (ESAS) to measure symptoms at baseline, week-2, and 3 months post-HCT. We measured post-traumatic stress (PTSD) symptoms using the PTSD checklist at baseline and 3 months post-HCT. We used linear regression models controlling for baseline values to assess the intervention effects on outcomes at week-2 and 3 months post-HCT. Results: Between 8/2014 and 1/2016, we enrolled 160/186 (86%) of potentially eligible patients. At week-2, the intervention led to improvements in QOL, depression, anxiety, and symptom burden. At 3 months post-HCT, the intervention led to improvements in QOL, depression, and PTSD [Table 1]. PHQ-9 scores at week-2 and HADS-anxiety scores at 3 months did not differ significantly. Conclusions: Palliative care improved QOL, depression, anxiety, and symptom burden in patients hospitalized for HCT with notable sustained effects 3 months post-HCT. Involvement of palliative care for patients with hematologic malignancies can improve their outcomes and substantially reduce the morbidity of HCT. Clinical trial information: NCT02207322. [Table: see text]
Clinicopathologic characteristics of patients with appendiceal adenocarcinoma (AA) and intra-thoracic metastasis.
Authors: Joshua S. Hill, Safia Rafeeq, David C. Rice, Michael J. Overman, Richard E. Royal, Paul F. Mansfield, Keith F. Fournier
Journal: Journal of Clinical Oncology (2012)

427 Background: Appendiceal adenocarcinoma (AA) is a rare disease with a prognosis related to tumor histology. Distant metastases, including those to the lung or pleura, are considered rare. We investigated the clinical characteristics and survival in patients with AA and intra-thoracic metastases. Methods: All patients with a pathologic diagnosis of AA who were evaluated at a single institution between September 1993 and July 2009 were retrospectively reviewed to identify patients with intra-thoracic metastasis. Parameters evaluated included demographics, histologic subtype and location of thoracic metastasis (parenchyma vs. pleural). Survival was calculated using the Kaplan-Meier method. Results: We evaluated 626 AA patients. Forty-two (6.7%) had intra-thoracic metastases: 24% pleural, 52 % parenchymal and 24% had both. Of those with intra-thoracic metastasis, the mean age at diagnosis was 54 years. Sixty percent were male. Histologic grade was: 19 (45%) low, 13 (31%) moderate and 9 (21%) grade high. Mean follow-up was 6.6 years. Median overall survival from diagnosis of the entire cohort was 5.2 years. Median overall survival by tumor grade: high 1.87 years, moderate 4.1 years, and not reached in low grade tumors (p=0.0001). The median overall survival from time of diagnosis of intra-thoracic metastasis is 1.44 years with survival by grade as follows: high-0.2 years, moderate-1.2 years, and low grade not reached (p=0.0003). Survival was not dependent on intra-thoracic location. Conclusions: Intra-thoracic metastasis in patients with AA occurs at a higher rate than previously thought, even in low grade tumors. This suggests that thoracic imaging should be considered in patients with AA. Overall survival depends heavily on tumor histology.
Quality-of-life concordance between patients with malignant gliomas and their caregivers: Updated data.
Authors: B. V. Stell, D. Jacobs, S. A. Grimm, A. Rademaker, L. Rice, M. A. Schwartz, K. Muro, M. H. Marymont, J. Chandler, I. B. Helenowski, L. I. Wagner, J. J. Raizer, C. L. Bennett
Journal: Journal of Clinical Oncology (2011)

9053 Background: Quality of Life (QOL) in patients diagnosed with malignant glioma is essential in the care of the patient. Patients often minimize many aspects of QOL; hence, caregiver input is valuable. Given the physical and cognitive decline experienced by malignant glioma patients, the primary caregiver plays a particularly important role in both daily assistance and communicating pertinent information to the treating physician. The purpose of this study was to assess the perspective the caregiver can provide regarding the quality of life of the patient, as well as quantify the burden on caregivers. Methods: The Functional Assessment of Cancer Therapy-Brain (FACT-Br) was administered separately to malignant glioma patients and their primary caregivers at 2-3 month intervals. Caregivers were directed to respond as they perceived the patient would. Additionally, the Caregiver Quality of Life Index-Cancer (CQOLC) was given to caregivers at baseline. Results: 178 pairs of FACT-Br scales were collected over the course of the study from 44 patient-caregiver pairs. A consistent discrepancy between patient and caregiver was seen, in that patients reported their overall quality of life (QOL) to be better than perceived by their caregivers by an average of 4.3 points on the 200 point scale (p=.02). Significant differences were found within subscales of physical (p<.01), social (p=.03), emotional (p=.02), and functional (p<.01) well-being. On the CQOLC, caregivers surveyed scored an average of 80.8 on the 140 point scale. This is significantly lower (p=.01) than the average for caregivers across all cancers (93.3). Caregivers in this sample responded most strongly regarding increased levels of stress and distress over seeing their loved one deteriorate. Conclusions: These results demonstrate the considerable benefit of caregiver participation in malignant glioma patients and also the degree of burden placed on them. Communicating with the caregiver can enable the physician to obtain a more comprehensive view of patient QOL to assess for interventions. In addition, since the burden is great for caregivers, more research needs to be done to understand this area and plan for early interventions for them.
Universal truths: Learning from the experience of cancer patients in Australia and England.
Authors: Karen Lacey, Penelope Schofield, Meinir Krishnasamy, Carrie Lethborg, Elizabeth Cashill, Eileen Thompson, Jill Butty, Adele Mollo, Assunta Morrone, Jenny Byrne, James F. Bishop
Journal: Journal of Clinical Oncology (2014)

255 Background: Self-reported patient experience data is vital to the design of responsive and relevant health services. Annual Cancer Patient Experience Surveys in England (NHS-CPES) have been used to effectively guide and monitor improvements in patient experience. This study measured baseline cancer patient experience in member hospitals of the Victorian Comprehensive Cancer Centre in Australia, and benchmarked this with cancer patients in England. Methods: The NHS-CPES instrument and methodology was used. A paper-based questionnaire was mailed to 5,722 admitted patients aged &gt;18 years with an eligible ICD-10 code. Australian results were compared to 71,793 patients in England from the 2011/12 NHS-CPES. Results: 37% (2,101) patients responded. Most patients rated their overall care as very good or excellent (91% Australia, 88% England). Having a named nurse specialist was a key predictor of experience. Patients with a specialist nurse were significantly more positive in 50 questions in Australia (77%) and 64 questions in England (98%) compared to patients without one. In both countries, patients with rarer cancers tended to be less positive than those with other cancer types. Australian patients with brain/central nervous system cancers and sarcomas gave the lowest score in 46 questions (71%). Patients with a disability or a long-term condition, and those from minority ethnic groups were also less positive. Relevant patient information was lacking; only 65% of patients in Australia and 77% in England were given understandable written information specific to their care, and a little over half received information about financial entitlements (58% Australia, 52% England). Conclusions: Cancer patient experience using the NHS-CPES has been successfully measured and compared across two different health systems. Findings in Australia are similar to those in England suggesting the same key issues affect all cancer patients. Important areas for quality improvement include the provision of tailored written patient information and the provision of named nurse specialists as part of the model of care. Acknowledgement: The authors thank Quality Health Limited for data analysis and the NHS for permitting use of the NHS-CPES.
Improving the AJCC/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histologic grade.
Authors: Michael J. Overman, Keith F. Fournier, Chung-Yuan Hu, Robert A. Wolff, Cathy Eng, Melissa W. Taggart, Richard E. Royal, Paul F. Mansfield, George J. Chang
Journal: Journal of Clinical Oncology (2012)

402 Background: Though histological grade is known to have a major prognostic impact in metastatic mucinous appendiceal adenocarcinomas; the prognostic impact of grade in localized disease, and the validity of the AJCC Cancer Staging Manual 7 th edition decision to combine moderately and poorly differentiated mucinous adenocarcinomas into a single mucinous high-grade category, is not known. Methods: Patients with adenocarcinoma of the appendix diagnosed between 1988-2007 were identified from the SEER database. Cancer-specific survival (CSS) stratified by histological subtype, stage and grade were calculated; and Cox proportional hazards regression analyses were performed. Results: We analyzed a total of 2,469 appendiceal adenocarcinomas, of which 1,375 had mucinous histology, 860 had non-mucinous histology, and 234 had signet-ring cell histology. Though overall CSS was similar for mucinous and non-mucinous subtypes, differences in stage distribution and stage-stratified CSS were seen. Female gender (57% vs.45%, P&lt;0.01), stage IV disease (48% vs. 25%, P&lt;0.01), and well differentiated histology (31% vs. 14%, P&lt;0.01) were more common in mucinous as compared to non-mucinous adenocarcinomas. While histological grade for stage I-III cases was not statistically significant, it had strong prognostic impact for stage IV disease. The adjusted hazard ratios for stage IV well, moderately and poorly differentiated histological grade were 1 (reference), 1.63 (95%CI: 1.14-2.34) and 4.94 (95%CI: 3.32-7.35) for mucinous, in comparison to 1 (reference), 1.44 (95%CI: 0.82-2.52) and 1.90 (95%CI: 0.95-3.80) for non-mucinous histological subtypes, respectively. Conclusions: The strong prognostic impact of histological grade for mucinous adenocarcinomas is primarily restricted to stage IV disease. Stage IV moderately and poorly differentiated mucinous adenocarcinomas have distinctly different CSS and this data does not support the combination of these two histological grades in the recent AJCC 7 th edition.
Variation in <i>TRMT11 </i>gene as a prognostic marker in advanced-stage castrate-resistant prostate cancer (CRPC) patients.
Authors: Ben Yiming Zhang, Shaun M. Riska, Douglas W. Mahoney, Ricardo Jorge Teixeira Ribeiro, Rui Medeiros, Catia Monteiro, James Robert Cerhan, Brian Addis Costello, Roxana Stefania Dronca, Fernando Quevedo, Henry Clement Pitot, Timothy J. Moynihan, Joaquina Mauricio, Avelino Manuel Fraga, Fernando Eduardo Calais Da Silva, Samith Thomas Kochuparambil, Manish Kohli
Journal: Journal of Clinical Oncology (2015)

255 Background: In a prior study, we found that 8 single nucleotide polymorphisms (SNPs) from 4 candidate hormone-related genes (JAK2, TRMT11, NKX3-1 and HSD17B12) were associated with overall survival (OS) in CRPC stage in a North American cohort of 519 subjects. We attempt to replicate these findings in an independent cohort of Portuguese patients. Methods: A hundred and forty CRPC stage patients in the new cohort were genotyped fort he candidate SNPs. The primary endpoint was overall survival (OS), defined as time from development of CRPC to death. For SNP level results we estimated hazard ratios (HR) and 95% confidence intervals (CI) under the dominant allele model using Cox regression and adjusted for age and Gleason score (GS). Results: The median age of the Portuguese cohort was 69 years (range 53-84). The GS distribution was 48% subjects with GS≥8; 35% with GS=7 and 17% with GS&lt;7. Median time from castration resistance to death for the cohort was 2.2 years (IQ range: 0.8-3.4, 93 deaths). One of the 3 SNPs (rs2295005; C&gt;G; MAF = 0.16) in the TRMT11gene was associated with OS after adjustment for age and GS: (dominant model p=0.05, HR=0.56; 95 CI=0.31-1.00). No other SNP was observed to have statistical significance with OS (Table 1). Conclusions: Variation in the TRMT11 gene is significantly associated with overall survival in patients with CRPC and warrants further validation as a potential prognostic biomarker. [Table: see text]
Increased Apoptosis of Peripheral Blood and Bone Marrow B and T Cells Correlates with Advanced Stages and Poor Risk Factors in Patients with B-CLL
Authors: Malgorzata Sieklucka, Agnieszka Bojarska-Junak, Agata Surdacka, Iwona Hus, Ewa Wasik-Szczepanek, Anna Dmoszynska, Malgorzata Wach, Magdalena Lewandowska, Jacek M. Rolinski
Journal: Blood (2008)
Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.
Authors: Edward Samuel James, Gina G. Chung, Michael DiGiovanna, Tara Beth Sanft, Erin Wysong Hofstatter, Noelle Sowers, Mary Beth Clark, Rebecca Lilian, Susan Chmael, Michelle Cappiello, Gineesha Abraham, Gary M Israel, Lajos Pusztai, Lyndsay Harris, Maysa M. Abu-Khalaf
Journal: Journal of Clinical Oncology (2013)

2587 Background: Synergy between histone deacetylase inhibitors and 5-fluorouracil is thought to be due to down regulation of thymidylate synthase. Study objectives are to assess maximum tolerated dose (MTD), dose limiting toxicities (DLT) and objective response rate of vorinostat (V) in combination with capecitabine (C). Secondary aims are pharmacodynamics of V. Methods: Cohorts of 3-6 patients (pts) were enrolled on a 3+3 dose-escalation phase to assess MTD of escalating doses of oral C (1500/1800/2000mg) with V 200 mg BID on days 1-7 and 15-21 of a 28 d cycle. 10 pts enrolled on dose expansion phase and treated at MTD. Pts received a “run in” treatment of V for 5 d and pre/post V biopsy (bx) collected when feasible. DLT was defined as ≥ grade 3 non hematological toxicity, grade 4 thrombocytopenia, grade 4 neutropenia &gt; 5 d, grade 4 febrile neutropenia requiring hospitalization, QTc &gt;500ms,or treatment delay &gt; 2 weeks from toxicity. Microarray analysis was performed using Illumina HT-12 gene arrays on pre/post bx from 4 pts. Results: 23 ptswith median age 51 (range 33-69) were treated: 8 pts at 1500/200mg, 5 pts at 1800/200mg, and 10 pts treated on dose expansion phase at 1500/200mg. Median # of prior lines of chemotherapy was 2 (range 0-7). 3 pts are still on study. Median # of cycles on study were 2 (range 1-42). Cycle 1 DLT was grade 3 fatigue in 2 pts treated on 1800/200mg, and in 1 pt treated on 1500/200mg. Other grade 3/4 toxicities are summarized in the Table. 14 pts are evaluable for response (12 pts at 1500/200mg and 2 pts at 1800/200mg). No objective responses were seen, 3 pts had stable disease &gt; 6 months (1 pt completed 42 cycles). Changes in pathways involved in extracellular matrix and TGFb pathway were noted. Conclusions: DLT of C concomitant with V was fatigue. MTD was 1500 mg C combined with 200 mg V BID. Combination has modest clinical activity. Consistent modulation of pathways involved in extracellular matrix and TGFb pathway, suggesting biomarkers of response to V. Clinical trial information: NCT00719875. [Table: see text]
Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD+C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell Lymphoma Patients (MCL): Prognostic Value of FDG-PET/CT
Authors: Julien Dubreuil, Roch Houot, Steven Le Gouill, Christiane Mounier, Stéphane Courby, Caroline Dartigeas, Krimo Bouabdallah, Marie Pierre Moles, Alexis Magda, Olivier Tournilhac, Mario Ojeda Uribe, Jean Cyril Bourre, Caroline Bodet-Milin, Jean-Philippe Vuillez, Remy Gressin
Journal: Blood (2014)
Effects of adjuvant 5FU/oxaliplatin chemotherapy in individuals treated for colon cancer on cognitive and mobility function.
Authors: Howard John Lim, Negin Niksirat, Stanley Hung, Sarah Neil-Sztramko, Teresa Liu-Ambrose, Todd Handy, Sherri Hayden, Sharlene Gill, Kristin L. Campbell
Journal: Journal of Clinical Oncology (2016)

750 Background: Cognitive impairment has been reported for patients receiving chemotherapy; however, the data is limited with respect to 5FU/oxaliplatin based therapy in colorectal cancer patients. We conducted a pilot study to determine if there was cognitive or mobility impairment in patients receiving adjuvant 5Fu/oxaliplatin chemotherapy. Methods: At baseline, end of chemotherapy and 6 months post chemotherapy, participant completed a neuropsychological test battery, which included the Stroop, Hopkins Verbal Learning Test-Revised (HVLT-R), and Trail Making A &amp; B (TMT A&amp;B), a 6-minute walk test (6MWT), a measure of physical function, and a functional mobility testing battery, which included timed up and go (TUG) and gait speed. Demographic information and self-reported physical activity, using the International Physical Activity Questionnaire (IPAQ), were also collected at these time points. For the analysis of neuropsychological and mobility test scores, the paired t-test was used to test for the differences and assess the change in the mean scores from the baseline, 6-months and 12 months. Results: 13 patients were enrolled, 10 have completed the 12 month evaluation. No significant changes were noted in the HVLT-R, Stroop, and TMT-A and -B mean scores after completion of chemotherapy compared to baseline. Compared to baseline, no significant changes were observed for 6MWT, TUG, GS, or leisure-time physical activity after completion of chemotherapy. Conclusions: In this small pilot study, there were no significant changes in chemotherapy-associated cognitive, physical function, or functional mobility noted from baseline to the end of chemotherapy. In addition, physical activity levels and average time spent sitting did not change significantly.
A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. Placebo+G-CSF in Non-Hodgkin’s Lymphoma (NHL) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.
Authors: John F. DiPersio, Ivana Micallef, Patrick J. Stiff, Brian J. Bolwell, Richard Thomas Maziarz, J. Angell, G. Bridger, Gary Calandra
Journal: Blood (2007)
Delayed Embryonic to Adult Globin Switching in HMGB2 Knock Out Mice
Authors: Giuseppina M. Marini, Isadora Asunis, Annalisa Cabriolu, Loredana Porcu, Anna Maria Sau, Francesca Manchinu, Susanna Porcu, Franca M. Marongiu, Daniela Poddie, Lorenza Ronfani, Marco Bianchi, Anotonella Ronchi, Maria Serafina Ristaldi, Antonio Cao, Paolo Moi
Journal: Blood (2011)
An open label phase II study of modified vaccinia ankara (MVA) expressing the tumor antigen 5T4 given in conjunction with chemotherapy: Safety and immunogenicity before, during and after chemotherapy
Authors: R. Harrop, R. Hawkins, A. Anthoney, N. Steven, N. Habib, S. Naylor, M. Carroll, S. Kingsman
Journal: Journal of Clinical Oncology (2005)

2578 Background: 5T4 is a tumour associated antigen that is widely expressed on the surface of most human adenocarcinomas, including colorectal, but rarely in normal cells. Modified Vaccinia Ankara (MVA) has been employed as a vaccine vector to deliver 5T4 (TroVax). Previously, TroVax has been evaluated in a phase I/II clinical trial in Duke’s D colorectal cancer patients. TroVax was shown to be safe and well tolerated and induced 5T4 specific immune responses in most patients. Furthermore, periods of disease stabilisation up to 18 months were observed. Methods: Two phase II clinical trials were initiated in which TroVax was administered in conjunction with either 5-FU/leukovorin and irinotecan (TV2-Irinotecan trial) or 5-FU/leukovorin and oxaliplatin (TV2-Oxaliplatin) in patients with advanced colorectal cancer. Both trials are open label and entail the administration of up to 6 injections of TroVax, 2 prior to, 2 during and 2 post-chemotherapy. The primary objective is to assess the effect of repeat cycles of chemotherapy on the immunogenicity of TroVax. The secondary objective is to assess the safety profile of TroVax in combination with chemotherapy. Results: Recruitment to both trials is complete and an interim analysis of results has been undertaken on all patients who have received ≥4 TroVax injections (n=14 for TV2-Irinotecan and n=7 for TV2-Oxaliplatin). TroVax has been well tolerated with the majority of product related adverse events, being associated with injection site reactions. In the TV2-Irinotecan trial, 9 patients showed positive proliferative responses to 5T4 protein and 7 mounted antibody responses. In the TV2-Oxaliplatin trial, 2 patients showed positive proliferative responses to 5T4 protein and 4 mounted 5T4-specific antibody responses. Conclusions: An interim analysis of the data indicates that TroVax is safe and well tolerated when administered in conjunction with 5-FU/leukovorin and irinotecan or 5-FU/leukovorin and oxaliplatin. Furthermore, 5T4 specific immune responses are induced in the majority of patients and can be boosted or maintained during standard chemotherapy regimens. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Oxford BioMedical
Pediatric Myelodysplastic Syndrome and Juvenile Myelomonocytic Leukemia in Korea: A Nation-Wide, Multicenter, Retrospective Study.
Authors: Hoon Kook, Dong Kyun Han, Hyeong Jin Kang, Bin Cho, Nak Gyun Chung, Ho Jun Im, Hyeon Jin Park, Jun Eun Park, Keon Hee Yoo
Journal: Blood (2007)